🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

76 results for “General” Clear

  1. Placebo efgartigimod IV concentrate for solution, ARGX-113, Vyvgart 20 mg/mL concentrate for solution for infusion

    argenx

    Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  2. Placebo to Descartes-08, Descartes-08

    Cartesian Therapeutics

    generalized myasthenia gravis

    phase 3 small molecule active

    1 trial

  3. Placebo to Remibrutinib (LOU064) 00 mg film-coated tablet, LOU064

    Novartis Pharmaceuticals

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  4. Pozelimab + Cemdisiran

    Regeneron UK Limited

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  5. Shingrix powder and suspension for suspension for injection Herpes zoster vaccine (recombinant, adjuvanted), Cladribine Placebo, cladribine

    Merck Sharp and Dohme

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  6. Sugammadex 100 mg/ml solution for injection, Rocuronium bromide 10 mg/ml solution for injection/infusion

    Istituto Gentili S.r.l.

    patients scheduled to undergo elective surgical procedures with general anesthesia

    phase 3 small molecule active

    1 trial

  7. TAK-279

    Takeda

    Generalized Pustular Psoriasis

    phase 3 small molecule active

    1 trial

  8. Telitacicept

    Vor Biopharma

    Generalized Myasthenia Gravis

    phase 3 mab active

    1 trial

  9. Vortioxetine

    Takeda

    Generalized Anxiety Disorder

    phase 3 small molecule completed

    3 trials

  10. Vyvgart 1 000 mg solution for injection

    argenx

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  11. Vyvgart 20 mg/mL concentrate for solution for infusion

    argenx

    Generalized Myasthenia Gravis (gMG)

    phase 3 small molecule active

    1 trial

  12. Vyvgart 20 mg/mL concentrate for solution for infusion

    argenx

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  13. XEN1101

    Xenon Pharmaceuticals

    Primary Generalized Tonic-Clonic Seizures

    phase 3 small molecule active

    1 trial

  14. Zilbrysq 23 mg solution for injection in pre-filled syringe, Zilucoplan sodium, -, Zilbrysq 16.6 mg solution for injection in pre-filled syringe, Zilbrysq 32.4 mg solution for injection in pre-filled syringe

    Lacuna Pharma Pty Ltd

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  15. Zilbrysq 32.4 mg solution for injection in pre-filled syringe, Zilbrysq 23 mg solution for injection in pre-filled syringe, Zilbrysq 16.6 mg solution for injection in pre-filled syringe

    Lacuna Pharma Pty Ltd

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  16. Zilbrysq 32.4 mg solution for injection in pre-filled syringe, Zilbrysq 23 mg solution for injection in pre-filled syringe, Zilucoplan sodium, -, Zilbrysq 16.6 mg solution for injection in pre-filled syringe

    Lacuna Pharma Pty Ltd

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  17. Zilucoplan sodium

    Lacuna Pharma Pty Ltd

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  18. adoptive immunotherapy

    Chinese PLA General Hospital

    Hepatocellular Carcinoma

    phase 3 mab completed

    1 trial

  19. mycophenolate mofetil (CellCept)

    Hoffmann-La Roche

    Myasthenia Gravis, Generalized

    phase 3 small molecule completed

    1 trial

  20. ARGX-117, ARGX-113

    argenx

    AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG

    phase 2 small molecule active

    1 trial

  21. AUR200, Isotone Natriumchloridlösung 0,9 % Braun Injektionslösung

    Aurinia Pharmaceuticals

    Generalized Myasthenia Gravis

    phase 2 small molecule active

    1 trial

  22. Aritinercept

    Aurinia Pharmaceuticals

    Myasthenia Gravis, Generalized

    phase 2 small molecule active

    1 trial

  23. DNTH103

    Dianthus Therapeutics, Inc. /DE/

    Myasthenia Gravis, Generalized

    phase 2 small molecule active

    1 trial

  24. Descartes-08

    Cartesian Therapeutics

    Myasthenia Gravis, Generalized

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources